Scarica l'app Stockscreener
37.51
0.61%
-0.23
Dopo l'orario di chiusura:
37.26
-0.25
-0.67%
Precedente Chiudi:
$37.74
Aprire:
$37.6
Volume 24 ore:
1.32M
Relative Volume:
2.13
Capitalizzazione di mercato:
$2.63B
Reddito:
-
Utile/perdita netta:
$-195.21M
Rapporto P/E:
-11.81
EPS:
-3.1763
Flusso di cassa netto:
$-176.19M
1 W Prestazione:
+5.19%
1M Prestazione:
+7.66%
6M Prestazione:
+44.88%
1 anno Prestazione:
+61.33%
Intervallo 1D:
$37.00
$39.03
Intervallo di 1 settimana:
$35.21
$43.25
Portata 52W:
$20.65
$43.25
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
37.51 | 2.65B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Wolfe Research | Outperform |
| 2026-03-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-10-15 | Iniziato | H.C. Wainwright | Buy |
| 2025-10-09 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Iniziato | Guggenheim | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Iniziato | Wedbush | Outperform |
| 2023-08-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Iniziato | Bryan Garnier | Buy |
| 2022-09-13 | Ripresa | JMP Securities | Mkt Outperform |
| 2022-08-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-02 | Iniziato | BofA Securities | Neutral |
| 2021-03-02 | Iniziato | Morgan Stanley | Overweight |
| 2021-03-02 | Iniziato | Oppenheimer | Outperform |
| 2021-03-02 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Pharvaris Nv Borsa (PHVS) Ultime notizie
Pharvaris (PHVS) Reports an 83% HAE Attack-Rate Reduction. Can Oral Convenience Win? - Yahoo Finance
Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary AngioedemaSlideshow (NASDAQ:PHVS) 2026-09-10 - Seeking Alpha
Pharvaris (NASDAQ: PHVS) officer to sell 30,000 shares in September 2026 - Stock Titan
Pharvaris at Cantor Fitzgerald conference: oral HAE push gains momentum - Investing.com
PHVS Maintained by Guggenheim -- Price Target Raised to $44.00 - GuruFocus
Guggenheim raises Pharvaris stock price target on trial results - Investing.com
Guggenheim raises Pharvaris stock price target on trial results By Investing.com - Investing.com India
Pharvaris at Wells Fargo conference: oral HAE drug gains ground - Investing.com
Pharvaris at Wells Fargo conference: oral HAE drug gains ground By Investing.com - Investing.com Nigeria
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com Nigeria
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com Australia
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com Nigeria
Pharvaris (NASDAQ: PHVS) director plans to sell shares from option exercise - Stock Titan
PHVS Maintained by Morgan Stanley -- Price Target Raised to $62. - GuruFocus
Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win - Seeking Alpha
Pharvaris stock gets $60 target at H.C. Wainwright on trial data By Investing.com - Investing.com South Africa
Pharvaris N.V. Announces 83% Decrease in Monthly HAE Attacks with Deucrictibant XR (NASDAQ: PHVS) - Kalkine Media
Pharvaris preps for MAA on deucrictibant data for HAE - BioWorld News
PHVS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy - allsci.com
RBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens raises Pharvaris stock price target to $79 on HAE therapy - Investing.com Nigeria
Insider at Pharvaris (PHVS) lines up new stock sale - Stock Titan
Pharvaris N.V. (PHVS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why is Pharvaris stock surging today? By Investing.com - Investing.com Australia
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is Pharvaris stock surging today? - Investing.com
Why Is Pharvaris Stock Soaring Tuesday? - Benzinga
Premarket Movers for Sept. 8, 2026: Notable Gainers and Losers - ChartMill
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones - TipRanks
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
Rare swelling attacks plunge in Pharvaris (PHVS) pill trial, with key U.S. drug decisions slated for 2027. - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pharvaris reports positive phase 3 results for HAE drug By Investing.com - Investing.com Nigeria
Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ) - Seeking Alpha
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR - TipRanks
Pharvaris stock surges 27% on positive trial data By Investing.com - Investing.com South Africa
Pharvaris stock surges 27% on positive trial data - Investing.com
Pharvaris reports positive phase 3 results for HAE drug - Investing.com
Pharvaris Announces Positive Topline Data from CHAPTER-3 - GlobeNewswire
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - MarketBeat
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Pharvaris (PHVS) Pulls Back 4.5% to $35.32 as Shares Approach Key SupportFibonacci Time Zone - vinanet.vn
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighWhat's Next? - MarketBeat
Foresite Capital Management V, LLC's Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris CEO Berndt Modig Sells 2,292 Shares Under Rule 10b5-1 Trading Plan - Kalkine Media
Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares - MarketBeat
Pharvaris (PHVS) CEO sells 2,292 shares after RSU vesting - Stock Titan
What is HC Wainwright's Forecast for Pharvaris Q3 Earnings? - MarketBeat
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris Nv Azioni (PHVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):